Overview

• The UK price increase has taken effect with some tirzepatide doses rising by up to 170%, including a move from £122 to £330 for a month’s supply of the highest strength.
• Pharmacies reported a rush of repeat orders and record prescription volumes as users sought to secure supplies before the hike.
• A Chemist4U survey found 44% of users would consider moving to Wegovy if costs become unsustainable, with pharmacists urging patients to consult clinicians before switching.
• Research cited by the British Heart Foundation reports average weight loss of just over 20% on Mounjaro versus nearly 14% on Wegovy, highlighting clinical trade‑offs beyond price.
• City of London Police and UK Border Force reported seizures of illegal weight‑loss drugs, as the Independent Pharmacies Association warned that patients priced out risk surgery delays and urged ministers to press Eli Lilly to restore supplies.